Pharmaceutical quality of generic isotretinoin products, compared with Roaccutane
Authors:
- 14 February 2006
- journal article
- research article
- Published by Taylor & Francis in Current Medical Research and Opinion
- Vol. 22 (3) , 603-615
Abstract
Isotretinoin is the drug of choice for the management of severe recalcitrant nodular acne. Several generic products are available. However, their pharmaceutical quality, in particular particle size distribution, which may affect safety and efficacy is unknown. Hence, prescribing of some generic products may be problematic. To assess the pharmaceutical quality of 14 generic isotretinoin products compared with Roaccutane (F. Hoffmann-La Roche Ltd). Tests were performed according to Roche standard procedures, European and US pharmacopoeia specifications. Tests included isotretinoin content, identity and amount of impurities and degradation products, effect of accelerated shelf-life studies on stability, particle size distribution and composition of non-active ingredients. The 14 isotretinoin products differed by 30-fold in median particle size and showed variation in their non-active ingredients. The average isotretinoin content of Acnotin and Acne-Tretin fell outside the 95-105% Roche specifications. Following accelerated shelf-life tests, only four products retained isotretinoin content within Roche specifications, whilst Acne-Tretin (the only powder formulation) lost 72.5% isotretinoin content. Two generic products exceeded the +/- 2% specification (Ph. Eur.) and a further three exceeded the +/- 1% (USP) for tretinoin content, eight exceeded the 2.54% specification for total impurities and six contained >or= 5 unknown impurities. Isotretinoin-5.6-epoxide content exceeded the 1.04% specification in five generic products. Thirteen generic products failed to match Roaccutane in one or more tests and 11 failed in three or more tests. It cannot be assumed that all generic isotretinoin products are as therapeutically effective or safe as Roaccutane.Keywords
This publication has 13 references indexed in Scilit:
- Safety assessment of esters of p-hydroxybenzoic acid (parabens)Food and Chemical Toxicology, 2005
- Accelerated photostability study of tretinoin and isotretinoin in liposome formulationsInternational Journal of Pharmaceutics, 2005
- Retinoid Therapy for AcneAmerican Journal of Clinical Dermatology, 2005
- Pharmaceutical Quality of Ceftriaxone Generic Drug Products Compared with Rocephin®Journal of Chemotherapy, 2003
- Effects of propyl paraben on the male reproductive systemFood and Chemical Toxicology, 2002
- A Survey of the Quality of Generic Clarithromycin Products from 13 CountriesClinical Drug Investigation, 2000
- Micronization: A method of improving the bioavailability of poorly soluble drugsMethods and Findings in Experimental and Clinical Pharmacology, 1998
- Retinoic Acid EmbryopathyNew England Journal of Medicine, 1985
- Isotretinoin therapy for acne: Results of a multicenter dose-response studyJournal of the American Academy of Dermatology, 1984
- A dose-response study of 13-cis-retinoic acid in acne vulgarisBritish Journal of Dermatology, 1983